Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases [Breast Cancer]

Conclusion
Although neratinib had low activity and did not meet our threshold for success, 12.5% of patients received six or more cycles. Studies combining neratinib with chemotherapy in patients with CNS disease are ongoing.

Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Freedman, Gelman, Wefel, Melisko, Hess, Connolly, Van Poznak, Niravath, Puhalla, Ibrahim, Blackwell, Moy, Herold, Liu, Lowe, Agar, Ryabin, Farooq, Lawler, Rimawi, Krop, Wolff, Winer, Lin Tags: Chemotherapy Breast Cancer Source Type: research